The Regeneron chief executive has backed an attempt by US regulators to block Amgen’s $28bn acquisition of Horizon Therapeutics as he accused some pharmaceutical companies of abusing their market power to prevent competition.
医药公司再生元(Regeneron)首席执行官支持美国监管机构阻止安进(Amgen)以280亿美元收购Horizon Therapeutics的企图。他指责一些制药公司滥用市场力量，阻碍竞争。
您已阅读7%（322字），剩余93%（4150字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。